Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone

European Urology

Volumn 65, Issue 1, 2014, Pages 30-36

  Schrader, Andres Jan ^a   Boegemann, Martin ^b   Ohlmann, Carsten H ^c   Schnoeller, Thomas J ^a   Krabbe, Laura Maria ^b   Hajili, Turkan ^c   Jentzmik, Florian ^a   Stoeckle, Michael ^c   Schrader, Mark ^a   Herrmann, Edwin ^b   Cronauer, Marcus V ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

Abiraterone; Biochemical failure; Cross resistance; Enzalutamide; MDV3100; Sequential therapy

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; DOCETAXEL; ENZALUTAMIDE; KETOCONAZOLE; PROSTATE SPECIFIC ANTIGEN; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; PHENYLTHIOHYDANTOIN; TAXOID;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; HUMAN; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BLOOD; DISEASE COURSE; MIDDLE AGED; PILOT STUDY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TREATMENT FAILURE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROSTENOLS; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; PHENYLTHIOHYDANTOIN; PILOT PROJECTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS; TREATMENT FAILURE;

EID: 84888852048     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.06.042     Document Type: Article

References (30)

1. N. Mottet, J. Bellmunt, and M. Bolla EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer Eur Urol 59 2011 572 583
2. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
3. J.S. de Bono, S. Oudard, and M. Ozguroglu Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
4. B.J. Feldman, and D. Feldman The development of androgen-independent prostate cancer Nat Rev Cancer 1 2001 34 45
5. J. Cheng, Y. Wu, J.L. Mohler, and C. Ip The transcriptomics of de novo androgen biosynthesis in prostate cancer cells following androgen reduction Cancer Biol Ther 9 2010 1033 1042
6. K. Fizazi, H.I. Scher, and A. Molina Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol 13 2012 983 992
7. G. Sonpavde, G. Attard, and J. Bellmunt The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature Eur Urol 60 2011 270 278
8. C. Tran, S. Ouk, and N.J. Clegg Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 324 2009 787 790
9. R. Leibowitz-Amit, and A.M. Joshua Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions Curr Oncol 19 Suppl 3 2012 S22 S31
10. H.I. Scher, K. Fizazi, and F. Saad Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
11. Y. Loriot, D. Bianchini, and E. Ileana Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) Ann Oncol 24 2013 1807 1812
12. K.L. Noonan, S. North, R.L. Bitting, A.J. Armstrong, S.L. Ellard, and K.N. Chi Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide Ann Oncol 24 2013 1802 1807
13. R.B. Montgomery, E.A. Mostaghel, and Robert Vessella Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth Cancer Res 68 2008 4447 4454
14. S. Haile, and M.D. Sadar Androgen receptor and its splice variants in prostate cancer Cell Mol Life Sci 68 2011 3971 3981
15. E. Hornberg, E.B. Ylitalo, and S. Crnalic Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival PLoS One 6 2011 e19059
16. J. Céeraline, M.D. Cruchant, and E. Erdmann Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer Int J Cancer 108 2004 152 157
17. W. Streicher, F. Zengerling, and M. Laschak AR-Q640X, a model to study the effects of constitutively active C-terminally truncated AR variants in prostate cancer cells World J Urol 30 2012 333 339
18. S.J. Libertini, C.G. Tepper, V. Rodriguez, D.M. Asmuth, H.J. Kung, and M. Mudryj Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence Cancer Res 67 2007 9001 9005
19. S. Sun, C.C. Sprenger, and R.L. Vessella Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant J Clin Invest 120 2010 2715 2730
20. E.A. Mostaghel, B.T. Marck, and S.R. Plymate Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants Clin Cancer Res 17 2011 5913 5925
21. R. Hu, C. Lu, and E.A. Mostaghel Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer Cancer Res 72 2012 3457 3462
22. Y. Li, S.C. Chan, L.J. Brand, T.H. Hwang, K.A. Silverstein, and S.M. Dehm Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines Cancer Res 73 2013 483 489
23. C. Cai, S. Chen, and P. Ng Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors Cancer Res 71 2011 6503 6513
24. J. Ishioka, S. Hara, J.T. Isaacs, A. Tomura, K. Nishikawa, and Y. Kageyama Suppression of mutant androgen receptors by flutamide Int J Urol 16 2009 516 521
25. C.D. Chen, D.S. Welsbie, and C. Tran Molecular determinants of resistance to antiandrogen therapy Nat Med 10 2004 33 39
26. J. Zhou, B. Liu, G. Geng, and J.H. Wu Study of the impact of the T877A mutation on ligand-induced helix-12 positioning of the androgen receptor resulted in design and synthesis of novel antiandrogens Proteins 78 2010 623 637
27. T. Hara, J. Miyazaki, and H. Araki Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome Cancer Res 63 2003 149 153
28. M.D. Balbas, M.J. Evans, and D.J. Hosfield Overcoming mutation-based resistance to antiandrogens with rational drug design Elife 2 2013 e00499
29. D.T. Miyamoto, R.J. Lee, and S.L. Stott Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer Cancer Discov 2 2012 995 1003
30. M.D. Sadar Advances in small molecule inhibitors of androgen receptor for the treatment of advanced prostate cancer World J Urol 30 2012 311 318